JP6417403B2 - Ａｃｃ阻害剤及びその使用 - Google Patents

Ａｃｃ阻害剤及びその使用 Download PDF

Info

Publication number
JP6417403B2
JP6417403B2 JP2016513086A JP2016513086A JP6417403B2 JP 6417403 B2 JP6417403 B2 JP 6417403B2 JP 2016513086 A JP2016513086 A JP 2016513086A JP 2016513086 A JP2016513086 A JP 2016513086A JP 6417403 B2 JP6417403 B2 JP 6417403B2
Authority
JP
Japan
Prior art keywords
compound
membered
compounds
sulfur
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016513086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520065A5 (enExample
JP2016520065A (ja
Inventor
ロバート グリーンウッド，ジェレミー
ロバート グリーンウッド，ジェレミー
シー． ハーリマン，ジェラルディン
シー． ハーリマン，ジェラルディン
ボルグ，ジョージ
イー． マッセ，クレイグ
イー． マッセ，クレイグ
Original Assignee
ギリアド アポロ， エルエルシー
ギリアド アポロ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51867755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6417403(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ギリアド アポロ， エルエルシー, ギリアド アポロ， エルエルシー filed Critical ギリアド アポロ， エルエルシー
Publication of JP2016520065A publication Critical patent/JP2016520065A/ja
Publication of JP2016520065A5 publication Critical patent/JP2016520065A5/ja
Application granted granted Critical
Publication of JP6417403B2 publication Critical patent/JP6417403B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/76—1,3-Oxazoles; Hydrogenated 1,3-oxazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016513086A 2013-05-10 2014-05-08 Ａｃｃ阻害剤及びその使用 Active JP6417403B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361821831P 2013-05-10 2013-05-10
US61/821,831 2013-05-10
PCT/US2014/037370 WO2014182951A1 (en) 2013-05-10 2014-05-08 Acc inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2016520065A JP2016520065A (ja) 2016-07-11
JP2016520065A5 JP2016520065A5 (enExample) 2017-07-06
JP6417403B2 true JP6417403B2 (ja) 2018-11-07

Family

ID=51867755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016513086A Active JP6417403B2 (ja) 2013-05-10 2014-05-08 Ａｃｃ阻害剤及びその使用

Country Status (14)

Country Link
US (1) US10208044B2 (enExample)
EP (1) EP2994141A4 (enExample)
JP (1) JP6417403B2 (enExample)
KR (1) KR20160005365A (enExample)
CN (1) CN105358155A (enExample)
AU (1) AU2014262547A1 (enExample)
BR (1) BR112015028214A2 (enExample)
CA (1) CA2911822A1 (enExample)
CL (1) CL2015003317A1 (enExample)
EA (1) EA201591962A1 (enExample)
HK (2) HK1221420A1 (enExample)
MX (1) MX2015015416A (enExample)
WO (1) WO2014182951A1 (enExample)
ZA (1) ZA201508355B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911932A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
MX2015015417A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
JPWO2015056782A1 (ja) 2013-10-17 2017-03-09 塩野義製薬株式会社 新規アルキレン誘導体
US20180021341A1 (en) 2015-01-09 2018-01-25 Gilead Apollo, Llc Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
AU2016359626A1 (en) 2015-11-25 2018-05-17 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine
EA201890913A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс Пиразоловые соединения в качестве ингибиторов акк и их применение
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
KR20180082557A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 트리아졸 acc 억제제 및 그의 용도
WO2018133858A1 (en) 2017-01-22 2018-07-26 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
EP3655409B1 (en) 2017-07-17 2023-12-27 Nanjing Ruijie Pharmatech Co., Ltd. Novel compounds and their uses as acc inhibitors
KR20190036705A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN110343650B (zh) * 2019-05-28 2020-12-29 浙江工业大学 一种产两性霉素b的重组结节链霉菌及其应用
WO2021000242A1 (zh) 2019-07-02 2021-01-07 广东东阳光药业有限公司 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB8524663D0 (en) 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0747582B2 (ja) 1989-12-11 1995-05-24 杏林製薬株式会社 キナゾリン―３―アルカン酸誘導体とその塩およびその製造法
US6069298A (en) 1993-02-05 2000-05-30 Regents Of The University Of Minnesota Methods and an acetyl CoA carboxylase gene for conferring herbicide tolerance and an alteration in oil content of plants
US6303181B1 (en) 1993-05-17 2001-10-16 Electrochemicals Inc. Direct metallization process employing a cationic conditioner and a binder
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6548738B2 (en) 2000-12-26 2003-04-15 Research Development Foundation ACC2-knockout mice and uses thereof
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20060100199A1 (en) 2002-06-06 2006-05-11 Seiji Yoshikawa Novel condensed imidazole derivatives
ATE425668T1 (de) 2003-01-06 2009-04-15 Yissum Res Dev Co Pflanzliche acetyl-coa carboxylase-hemmende herbizide als pestizide
US7423031B2 (en) 2003-05-01 2008-09-09 Irm Llc Compounds and compositions as protein kinase inhibitors
CN103333885A (zh) 2003-06-23 2013-10-02 先锋高级育种国际公司 将单基因控制的保绿潜力工程化进植物中
US7947691B2 (en) 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
JP2006131559A (ja) 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
JP5112316B2 (ja) 2005-08-10 2013-01-09 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP2009528389A (ja) 2006-03-02 2009-08-06 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシン受容体拮抗剤
MX2009000884A (es) 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
AR063417A1 (es) 2006-11-01 2009-01-28 Astrazeneca Ab Compuestos inhibidores del activador de plasminogeno tipo 1(pai-1)
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008103354A2 (en) 2007-02-20 2008-08-28 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
AU2008256717B2 (en) 2007-05-25 2013-11-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
EP2291377B1 (en) 2008-07-02 2015-02-18 Avexa Limited Imidazopyrimidinones and uses thereof
WO2010022236A2 (en) 2008-08-20 2010-02-25 The University Of Medicine And Dentistry Of New Jersey Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2010127212A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US8729102B2 (en) 2010-11-30 2014-05-20 Takeda Pharmaceutical Company Limited Bicyclic compound
PE20141187A1 (es) 2011-04-22 2014-09-18 Pfizer Inhibidores sustituidos de aeitl-coa carboxilasa
JPWO2013035827A1 (ja) * 2011-09-09 2015-03-23 塩野義製薬株式会社 新規オレフィン誘導体
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
ES2665580T3 (es) 2011-11-11 2018-04-26 Gilead Apollo, Llc Inhibidores de ACC y usos de los mismos
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CA2911932A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
MX2015015417A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.

Also Published As

Publication number Publication date
KR20160005365A (ko) 2016-01-14
HK1221420A1 (zh) 2017-06-02
EP2994141A1 (en) 2016-03-16
US10208044B2 (en) 2019-02-19
AU2014262547A1 (en) 2015-11-26
MX2015015416A (es) 2016-06-21
EP2994141A4 (en) 2016-11-23
CN105358155A (zh) 2016-02-24
HK1221662A1 (zh) 2017-06-09
CL2015003317A1 (es) 2016-07-29
CA2911822A1 (en) 2014-11-13
BR112015028214A2 (pt) 2017-07-25
ZA201508355B (en) 2017-09-27
WO2014182951A1 (en) 2014-11-13
EA201591962A1 (ru) 2016-06-30
US20160185783A1 (en) 2016-06-30
JP2016520065A (ja) 2016-07-11

Similar Documents

Publication Publication Date Title
JP6417402B2 (ja) Ａｃｃ阻害剤及びその使用
JP6417401B2 (ja) Ａｃｃ阻害剤及びその使用
JP6434498B2 (ja) Ａｃｃ阻害剤及びその使用
US10208044B2 (en) ACC inhibitors and uses thereof
CA3004796C (en) Pyrazole acc inhibitors and uses thereof
CA3004798C (en) Ester acc inhibitors and uses thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160621

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160915

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181005

R150 Certificate of patent or registration of utility model

Ref document number: 6417403

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250